Breast Cancer, Multi-parametric MRI, Neoadjuvant Chemotherapy, Radiomics
Conditions
Brief summary
This is a single-arm, multicentre study that aims to assess whether Radiomics combining multiparametric MRI and clinical data could be a good predictor of the responses to neoadjuvant chemotherapy in Breast Cancer.
Detailed description
Patients undergo multiparametric MRI (including T2WI, DWI and DCE-MRI) at baseline, after 2 courses of neoadjuvant chemotherapy, and prior to the surgery at least 8 weeks after the treatment procedure. Patients undergo biopsy test in one week after the baseline MRI scan to detect the biomarkers including ER, PR, Her-2 and Ki-67, which can be used to select the treatment plan referring to the NCCN clinical guidelines. After the surgery, responses to neoadjuvant chemotherapy are determined according to the histopathologically examination of the surgically resected specimens. After completion of treatment procedure, patients are followed up for 5 years.
Interventions
OTHERneoadjuvant chemotherapy
neoadjuvant chemotherapy
Sponsors
Guangdong Provincial People's Hospital
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Beijing Friendship Hospital
Yunnan Cancer Hospital
Liaoning Cancer Hospital & Institute
First Hospital of China Medical University
Affiliated Hospital of Hebei University
Chinese Academy of Sciences
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
FEMALE
Healthy volunteers
No
Inclusion criteria
* biopsy-proven invasive breast cancer; * received complete neoadjuvant chemotherapy and no treatment has been done before; * surgery was performed after completion of neoadjuvant chemotherapy, after which pCR was confirmed by postoperative pathological examination; * pretreatment MRI data within a month before the start of the treatment was eligible, including T2WI, DWI and DCE-MRI.
Exclusion criteria
* not completing neoadjuvant chemoradiotherapy; * not undergoing surgery at our hospital, or pCR was not assessed; * lack of T2WI, or DWI or DCE-MRI data; * insufficient MRI quality to obtain measurements (e.g., owing to motion artifacts); * had unilateral multifocal cancers, and the correlation between the tumor in MR images and postoperative pathological examination was uncertain.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| predicting pathological complete response (pCR) or no response (NR) | 20 weeks | The value of Radiomics of multiparametric MRI in predicting responses to neoadjuvant chemotherapy, including pathological complete response (pCR) and no response (NR). |
| 5 years for Disease free survival | 5 years | The association between Radiomics of multiparametric MRI and disease free survival (DFS), which defined as the time from the beginning of neoadjuvant chemotherapy to the confirmed time of recurrence or metastatic disease, or death due to any other cause. |
| 5 years for Overall survival | 5 years | The association between Radiomics of multiparametric MRI and overall survival (OS), which defined as the time from the beginning of neoadjuvant chemotherapy to the death with any causes. |
Countries
China
Contacts
Primary ContactZhenyu Liu, Doctor
Outcome results
None listed